Inclusion Body Myositis (IBM) is a rare and progressive muscle disorder primarily affecting older adults. It is estimated to affect approximately 1 to 9 individuals per million people worldwide. IBM is characterized by muscle weakness and wasting, particularly in the arms, legs, and throat. The exact cause of IBM is unknown, and there is currently no cure for the condition. However, certain treatments and therapies can help manage symptoms and improve quality of life for those affected. Early diagnosis and intervention are crucial for optimizing outcomes in individuals with IBM.
Inclusion Body Myositis (IBM) is a rare and progressive muscle disorder that primarily affects older adults. It is characterized by muscle weakness and wasting, particularly in the arms and legs. IBM is considered one of the most common acquired muscle diseases in individuals over the age of 50.
While the exact prevalence of IBM is uncertain, it is estimated to affect approximately 1 to 9 individuals per million worldwide. However, due to underdiagnosis and misdiagnosis, the true prevalence may be higher. IBM is more prevalent in men than women, and its incidence increases with age.
IBM is a chronic condition with no known cure. The disease progresses slowly over time, leading to significant disability and reduced quality of life. The exact cause of IBM is still unknown, but it is believed to involve a combination of genetic and environmental factors.
Early diagnosis and management of IBM are crucial to help alleviate symptoms and slow disease progression. Treatment typically involves a multidisciplinary approach, including physical therapy, medication, and assistive devices to improve mobility and maintain independence.